Orange Book product · Generic (ANDA)
LACOSAMIDE
LACOSAMIDE
At a glance
Apr 07, 2022
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Apr 07, 2022
4 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
LACOSAMIDE
Strength
200MG/20ML (10MG/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
AP
Application
ANDA 214301
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of LACOSAMIDE
- 2023MOTPOLY XRBrand (NDA)
NDA 216185 · AUCTA
- 2010VIMPATBrand (NDA)
NDA 022255 · UCB INC
- 2008VIMPATBrand (NDA)
NDA 022254 · UCB INC
- 2008VIMPATBrand (NDA)
NDA 022253 · UCB INC
- 2026LACOSAMIDEGeneric (ANDA)
ANDA 220366 · STERANCO HLTHCARE
- 2026LACOSAMIDEGeneric (ANDA)
ANDA 220386 · REGCON HOLDINGS
- 2026LACOSAMIDEGeneric (ANDA)
ANDA 220268 · GLENMARK PHARMS
- 2025LACOSAMIDEGeneric (ANDA)
ANDA 219699 · AJENAT PHARMS
- 2025LACOSAMIDEGeneric (ANDA)
ANDA 218706 · WESTMINSTER PHARMS
- 2024LACOSAMIDEGeneric (ANDA)
ANDA 218464 · ACELLA
- 2024LACOSAMIDEGeneric (ANDA)
ANDA 214960 · SOMERSET THERAPS LLC
- 2024LACOSAMIDEGeneric (ANDA)
ANDA 213109 · UNICHEM
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
